trials shortly to open

IPI-504 study - a phase 3, randomized, double-blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of IPI-504, an HSP90 inhibitor, as compared to placebo in patients with metastatic and/or unresectable gastrointestinal stromal tumour following failure of at least imatinib and sunitinib. Expected to open mid 2009.

AMN107 G 2301 - A randomized, open-label, multi-centre phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumours. Expected to open mid 2009.

Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumour of Bone (Amgen) – an open-label, multi-centre, phase II study of denosumab, a RANK ligand inhibitor, aiming to assess the safety profile of the drug, and to assess how many patients can limb or joint-sparing surgery for treatment of their giant cell tumour. Expected to open mid 2009.